Interleukin-2 receptor alpha

Model informed dosing regimen and phase I results of the anti-PD-1 antibody budigalimab (ABBV-181) (2020) Powderly J, Spira A, Kondo S, Doi T, Luke JL, Rasco D, Gao B, Tanner M, Cassier PA, Gazzah A, Italiano A, Tosi D, Afar DE, Parikh A, Engelhardt B, Englert S, Lambert SL, Kasichayanula S, Mensing S, Menon R, Vosganian G, Tolcher A Clinical and Translational Science

Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman disease. (2019) Fajgenbaum DC, Langan RA, Sada Japp A, Patridge HL, Pierson SK, Singh A, Arenas DJ, Ruth JR, Nabel CS, Stone K, Okumura M, Schwarer A, Jose FF, Hamerschlak N, Wertheim GB, Jordan MB, Cohen AD, Krymskaya V, Rubenstein A, Betts MR, Kambayashi T, van Rhee F, Uldrick TS The Journal of Clinical Investigation

Phase I Trial of the Pan-Pi3k Inhibitor Pilaralisib (Sar245408/Xl147) in Patients with Chronic Lymphocytic Leukemia (Cll) or Relapsed/Refractory Lymphoma (2015) Brown JR, Davids MS, Rodon J, Abrisqueta P, Kasar SN, Lager J, Jiang J, Egile C, Awan FT American Association for Cancer Research

Update on the Safety and Efficacy of the Pan Class I Pi3k Inhibitor Sar245408 (Xl147) in Chronic Lymphocytic Leukemia and Non-Hodgkin?s Lymphoma Patients (2013) Davids MS, Rodon J, Abrisqueta P, Egile C, Ruiz-Soto R, Awan F Blood